Excipient Impact on Fenofibrate Equilibrium Solubility in Fasted and Fed Simulated Intestinal Fluids Assessed Using a Design of Experiment Protocol.

chitosan design of experiment equilibrium solubility fenofibrate hydroxypropylmethylcellulose mannitol polyvinylpyrrolidone simulated fasted intestinal media simulated fed intestinal media

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
17 Oct 2023
Historique:
received: 14 07 2023
revised: 13 09 2023
accepted: 27 09 2023
medline: 28 10 2023
pubmed: 28 10 2023
entrez: 28 10 2023
Statut: epublish

Résumé

Solubility is a critical parameter controlling drug absorption after oral administration. For poorly soluble drugs, solubility is influenced by the complex composition of intestinal media and the influence of dosage form excipients, which can cause bioavailability and bioequivalence issues. This study has applied a small scale design of experiment (DoE) equilibrium solubility approach in order to investigate the impact of excipients on fenofibrate solubility in simulated fasted and fed intestinal media. Seven media parameters (bile salt (BS), phospholipid (PL), fatty acid, monoglyceride, cholesterol, pH and BS/PL ratio) were assessed in the DoE and in excipient-free media, and only pH and sodium oleate in the fasted state had a significant impact on fenofibrate solubility. The impact of excipients were studied at two concentrations, and for polyvinylpyrrolidone (PVP, K12 and K29/32) and hydroxypropylmethylcellulose (HPMC, E3 and E50), two grades were studied. Mannitol had no solubility impact in any of the DoE media. PVP significantly increased solubility in a media-, grade- and concentration-dependent manner, with the biggest change in fasted media. HPMC and chitosan significantly reduced solubility in both fasted and fed states in a media-, grade- and concentration-dependent manner. The results indicate that the impact of excipients on fenofibrate solubility is a complex interplay of media composition in combination with their physicochemical properties and concentration. The results indicate that in vitro solubility studies combining the drug of interest, proposed excipients along with suitable simulated intestinal media recipes will provide interesting information with the potential to guide formulation development.

Identifiants

pubmed: 37896244
pii: pharmaceutics15102484
doi: 10.3390/pharmaceutics15102484
pmc: PMC10610309
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Cancer Research UK
ID : 20740
Pays : United Kingdom

Références

Mol Pharm. 2015 Sep 8;12(9):3408-19
pubmed: 26214347
Mol Pharm. 2017 Dec 4;14(12):4170-4180
pubmed: 29072917
Eur J Pharm Biopharm. 2022 Aug;177:126-134
pubmed: 35718078
Eur J Pharm Biopharm. 2021 Nov;168:90-96
pubmed: 34419602
Eur J Pharm Sci. 2015 Jan 25;67:65-75
pubmed: 25444845
Int J Pharm. 2018 Aug 25;547(1-2):158-168
pubmed: 29758344
ISRN Pharm. 2012;2012:195727
pubmed: 22830056
Eur J Pharm Biopharm. 2019 Mar;136:147-155
pubmed: 30682491
J Pharm Sci. 2016 Feb;105(2):673-681
pubmed: 26228456
Saudi Pharm J. 2013 Jan;21(1):77-84
pubmed: 24109206
Eur J Pharm Biopharm. 2020 May;150:14-23
pubmed: 32035969
Biol Pharm Bull. 2006 Sep;29(9):1941-6
pubmed: 16946514
Eur J Pharm Sci. 2014 Jun 16;57:322-32
pubmed: 23994640
Drug Metab Pharmacokinet. 2007 Aug;22(4):225-54
pubmed: 17827779
J Pharm Pharmacol. 2010 Nov;62(11):1656-68
pubmed: 21039549
J Pharm Pharmacol. 2005 May;57(5):533-46
pubmed: 15901342
J Pharm Sci. 2018 Aug;107(8):2020-2032
pubmed: 29665381
J Colloid Interface Sci. 2019 Sep 1;551:147-154
pubmed: 31075629
J Pharm Pharmacol. 2002 Apr;54(4):487-92
pubmed: 11999125
Eur J Pharm Sci. 2016 Mar 31;85:10-7
pubmed: 26826280
Eur J Pharm Sci. 2017 Mar 1;99:95-104
pubmed: 27940083
Pharm Res. 1995 Mar;12(3):413-20
pubmed: 7617530
AAPS J. 2010 Sep;12(3):397-406
pubmed: 20458565
Pharmaceutics. 2020 Mar 08;12(3):
pubmed: 32182653
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Mol Pharm. 2011 Apr 4;8(2):564-70
pubmed: 21268663
AAPS J. 2017 Jul;19(4):989-1001
pubmed: 28516359
Eur J Pharm Biopharm. 2000 Jul;50(1):47-60
pubmed: 10840192
J Pharm Sci. 1985 Apr;74(4):416-21
pubmed: 3999002
Eur J Pharm Sci. 2011 Jul 17;43(4):260-9
pubmed: 21570465
Int J Clin Pharmacol Ther. 2019 Apr;57(4):217-228
pubmed: 30802201

Auteurs

Bayan E Ainousah (BE)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.

Ibrahim Khadra (I)

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK.

Gavin W Halbert (GW)

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK.

Classifications MeSH